Phase II Trial of the Impact 0.5% Povidone‐Iodine Nasal Spray (Nasodine®) on Shedding of SARS‐CoV‐2
Friedland et al., The Laryngoscope, doi:10.1002/lary.31430
https://c19early.org/friedland2.html